An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredutant 100 mg dose once daily, in elderly patients with major depressive disorder

Trial Profile

An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredutant 100 mg dose once daily, in elderly patients with major depressive disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2016

At a glance

  • Drugs Saredutant (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms INDIGO
  • Sponsors Sanofi
  • Most Recent Events

    • 26 Dec 2007 Status change from recruiting to in progress.
    • 15 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top